bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.18821/0234-5730-2017-62-1-15-19bloodjour-53Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESДИНАМИКА ВОССТАНОВЛЕНИЯ CD4+FOXP3+ Т-КЛЕТОК ПОСЛЕ ТРАНСПЛАНТАЦИИ АУТОЛОГИЧНЫХ ГЕМОПОЭТИЧЕСКИХ СТВОЛОВЫХ КЛЕТОК У БОЛЬНЫХ МНОЖЕСТВЕННОЙ МИЕЛОМОЙRECOVERY OF CD4+FOXP3+ T CELLS IN PATIENTS WITH MULTYPLE MYELOMA AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATIONhttps://orcid.org/0000-0003-2902-9336БаторовE. В.BatorovE. V.

Баторов Егор Васильевич, кандидат медицинских наук, научный сотрудник лаборатории клеточной иммунотерапии ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии», 630099, г. Новосибирск

Scopus Author ID 35768879800

Batorov Egor V., MD, PhD, researcher, Laboratory of Cellular Immunotherapy, Research Institute of Fundamental andClinical Immunology, Novosibirsk, 630090

Scopus Author ID 35768879800

Ebatorov@mail.ruhttps://orcid.org/0000- 0002-2366-1667ТихоноваМ. A.TikhonovaM. A.

630099, г. Новосибирск

Scopus Author ID 35508779900

Novosibirsk,630090

Scopus Author ID 35508779900

https://orcid.org/0000-0001-9981-0617КрючковаИ. В.KryuchkovaI. V.

630099, г. Новосибирск

Scopus Author ID 6506011822

Novosibirsk,630090

Scopus Author ID 6506011822

https://orcid.org/0000-0003-1951- 2260СергеевичеваВ. В.SergeevichevaV. V.

630099, г. Новосибирск

Scopus Author ID 54881246800

Novosibirsk,630090

Scopus Author ID 54881246800

https://orcid.org/0000-0001-7109-3839СизиковаС. A.SizikovaS. A.

630099, г. Новосибирск

Scopus Author ID 6506084173

Novosibirsk,630090

Scopus Author ID 6506084173

https://orcid.org/0000-0003-1822-6326УшаковаГ. Ю.UshakovaG. Yu.

630099, г. Новосибирск

Scopus Author ID 56528086500

Novosibirsk,630090

Scopus Author ID 56528086500

https://orcid.org/0000-0002-0792-3110ГилевичA. В.GilevichA. V.

630099, г. Новосибирск

Scopus Author ID 6602933794

Novosibirsk,630090

Scopus Author ID 6602933794

https://orcid.org/0000- 0001-6895-938XОстанинA. A.OstaninA. A.

630099, г. Новосибирск

https://orcid.org/0000-0003-2346- 6279ЧерныхЕ. Р.ChernykhE. R.

630099, г. Новосибирск

ResearcherID: K-1052-2014

Novosibirsk,630090

ResearcherID: K-1052-2014

ФГБНУ «Научно-исследовательский институт фундаментальной и клинической иммунологии»РоссияResearch Institute of Fundamental and Clinical ImmunologyRussian Federation2017080320196211519Copyright © Баторов E.В., Тихонова М.A., Крючкова И.В., Сергеевичева В.В., Сизикова С.A., Ушакова Г.Ю., Гилевич A.В., Останин A.A., Черных Е.Р., 20192019Баторов E.В., Тихонова М.A., Крючкова И.В., Сергеевичева В.В., Сизикова С.A., Ушакова Г.Ю., Гилевич A.В., Останин A.A., Черных Е.Р.Batorov E.V., Tikhonova M.A., Kryuchkova I.V., Sergeevicheva V.V., Sizikova S.A., Ushakova G.Y., Gilevich A.V., Ostanin A.A., Chernykh E.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/53

Работа посвящена изучению особенностей восстановления CD4+FOXP3+ Т-клеток периферической крови после высокодозной химиотерапии (ВХТ) с трансплантацией аутологичных гемопоэтических стволовых клеток (ауто-ТГСК) у больных множественной миеломой (ММ) и оценке прогностической значимости CD4+FOXP3+ Т-клеток в течение посттрансплантационного периода. Содержание циркулирующих CD4+FOXP3+ Т-клеток было исследовано у 59 больных ММ, которым проводили ВХТ с ауто-ТГСК. Количество CD4+FOXP3+ Т-клеток оценивали методом проточной цитометрии до ВХТ с ауто-ТГСК на момент выхода из лейкопении через 6 и 12 мес. Количество CD4+FOXP3+ Т-клеток полностью восстанавливалось и значимо превышало исходную концентрацию ко дню выхода из лейкопении. В последующем (в течение года) их относительное содержание постепенно снижалось до нормы. Анализ взаимосвязи CD4+FOXP3+ Т-клеток с исходами ауто-ТГСК показал, что больные с рецидивом ММ в течение первых 12 мес после ауто-ТГСК различались значимо более высоким относительным содержанием CD4+FOXP3+ Т-клеток на момент выхода из лейкопении. Проведение анализа характеристических кривых (receiver operating characteristic – ROC) выявило высокую прогностическую значимость оценки CD4+FOXP3+ Т-клеток как предиктора раннего развития рецидива заболевания после ВХТ с ауто-ТГСК. Таким образом, количество циркулирующих CD4+FOXP3+ Т-клеток после ауто-ТГСК восстанавливается быстро и полностью. Развитие раннего рецидива заболевания после ВХТ с ауто-ТГСК ассоциировано с более высоким содержанием CD4+FOXP3+ Т-клеток ко времени выхода из лейкопении. Повышенное содержание этих клеток позволяет прогнозировать развитие рецидива ММ в раннем посттрансплантационном периоде.

We have investigated the dynamics of post-transplant recovery of CD4+FOXP3+ T cells in patients with multiple myeloma (MM). The relationship between CD4+FOXP3+ T cell counts and clinical outcomes of MM patients after high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) also has been evaluated. Fifty-nine patients were included in the study. The content of circulating CD4+FOXP3+ T cells has been assessed with the use of flow cytometry before AHSCT, at the day of engraftment, and 6 and 12 months later. After AHSCT the relative count of CD4+FOXP3+T cells in MM patients restored rapidly, it became higher than initial level at the day of engraftment and then subsequently decreased for a 1 year to values in healthy donors. A relative count of CD4+FOXP3+T cellsat the time of engraftment increased in patients with relapsed disease during 12 months after AHSCT. Receiver operating characteristic (ROC) analysis showed that evaluation of CD4+FOXP3+ T cells at the day of engraftment allowed to predict the early relapse of MM after AHSCT.

множественная миеломатрансплантация аутологичных гемопоэтических стволовых клетокCD4+FOXP3+ Т-клеткирецидивmultiple myelomaautologous hematopoietic stem cell transplantationCD4+FOXP3+ T cellsrelapseReferencesБессмельцев С.С. Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз). Часть I. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2013; 6(3): 237–57Bessmeltsev S.S. Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I. Clinical Oncohematology. Fundamental research and clinical practice. Russian journal (Klinicheskaya oncogematologiya. Fundamentalnye issledovaniya i klinicheskaya praktika). 2013; 6(3): 237–57. (in Russian)Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5): 2516–20.Kumar S.K., Rajkumar S.V., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111(5): 2516–20.Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 2007; 138(5): 563–79.Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 2007; 138(5): 563–79.Mittal S., Marshall N.A., Duncan L., Culligan D.J., Barker R.N., Vickers M.A. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 2008; 111(11): 5359–70. doi: 10.1182/blood-2007-08-105395.Mittal S., Marshall N.A., Duncan L., Culligan D.J., Barker R.N., Vickers M.A. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood. 2008; 111(11): 5359–70. doi: 10.1182/blood-2007-08-105395.Heier I., Hofgaard P.O., Brandtzaeg P., Jahnsen F.L., Karlsson M. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin. Exp. Immunol. 2008; 152(2): 381–7.Heier I., Hofgaard P.O., Brandtzaeg P., Jahnsen F.L., Karlsson M. Depletion of CD4+ CD25+ regulatory T cells inhibits local tumour growth in a mouse model of B cell lymphoma. Clin. Exp. Immunol. 2008; 152(2): 381–7.Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour сell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012; 7(5): e35981.Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour сell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012; 7(5): e35981.Prabhala R.H., Neri P., Bae J.E., Tassone P., Shammas M.A., Allam C.K., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006; 107(1): 301–4.Prabhala R.H., Neri P., Bae J.E., Tassone P., Shammas M.A., Allam C.K., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006; 107(1): 301–4.Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 2006; 107(10): 3940–9.Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma. Blood. 2006; 107(10): 3940–9.Muthu Raja K.R., Rihova L., Zahradova L., Klincova M., Penka M., Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012; 7(10): e47077.Muthu Raja K.R., Rihova L., Zahradova L., Klincova M., Penka M., Hajek R. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PLoS One. 2012; 7(10): e47077.Foglietta M., Castella B., Mariani S., Coscia M., Godio L., Ferracini R., et al. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. Haematologica. 2014; 99(10): 1605–10.Foglietta M., Castella B., Mariani S., Coscia M., Godio L., Ferracini R., et al. The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. Haematologica. 2014; 99(10): 1605–10.Giannopoulos K., Kaminska W., Hus I., Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br. J. Cancer. 2012; 106(3): 546–52.Giannopoulos K., Kaminska W., Hus I., Dmoszynska A. The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. Br. J. Cancer. 2012; 106(3): 546–52.Atanackovic D., Cao Y., Luetkens T., Panse J., Faltz C., Arfsten J., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008; 93(3): 423–30.Atanackovic D., Cao Y., Luetkens T., Panse J., Faltz C., Arfsten J., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica. 2008; 93(3): 423–30.Ganeshan P., Gupta R., Hakim M., Kumar L., Bhaskar A., Sharma A. Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma. Int. J. Hematol. 2011; 94(6): 578–9.Ganeshan P., Gupta R., Hakim M., Kumar L., Bhaskar A., Sharma A. Reconstitution of regulatory T cells after autologous transplantation in multiple myeloma. Int. J. Hematol. 2011; 94(6): 578–9.Matsuoka K., Kim H. T., McDonough S., Bascug G., Warshauer B., Koreth J., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 2010; 120(5): 1479–93.Matsuoka K., Kim H. T., McDonough S., Bascug G., Warshauer B., Koreth J., et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 2010; 120(5): 1479–93.Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3): 842–54.Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3): 842–54.Feyler S., Selby P.J., Cook G. Regulating the regulators in cancerimmunosuppression in multiple myeloma (MM). Blood Rev. 2013; 27(3): 155-64.Feyler S., Selby P.J., Cook G. Regulating the regulators in cancerimmunosuppression in multiple myeloma (MM). Blood Rev. 2013; 27(3): 155-64.Haque R., Lei F., Xiong X., Song J. The regulation of FoxP3-expressing regulatory T cells. Endocr. Metab. Immune Disord. Drug Targets. 2011; 11(4): 334–46.Haque R., Lei F., Xiong X., Song J. The regulation of FoxP3-expressing regulatory T cells. Endocr. Metab. Immune Disord. Drug Targets. 2011; 11(4): 334–46.Kawano Y., Kim H.T., Matsuoka K., Bascug G., McDonough S., Ho V.T., et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011; 118(18): 5021–30.Kawano Y., Kim H.T., Matsuoka K., Bascug G., McDonough S., Ho V.T., et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011; 118(18): 5021–30.Shen S., Ding Y., Tadokoro C.E., Olivares-Villagómez D., CampsRamírez M., Curotto de Lafaille M.A., et al. Control of homeostatic proliferation by regulatory T cells. J. Clin. Invest. 2005; 115(12): 3517–26.Shen S., Ding Y., Tadokoro C.E., Olivares-Villagómez D., CampsRamírez M., Curotto de Lafaille M.A., et al. Control of homeostatic proliferation by regulatory T cells. J. Clin. Invest. 2005; 115(12): 3517–26.Winstead C.J., Fraser J.M., Khoruts A. Regulatory CD4+CD25+Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. J. Immunol. 2008; 180(11): 7305–17.Winstead C.J., Fraser J.M., Khoruts A. Regulatory CD4+CD25+Foxp3+ T cells selectively inhibit the spontaneous form of lymphopenia-induced proliferation of naive T cells. J. Immunol. 2008; 180(11): 7305–17.Winstead C.J., Reilly C.S., Moon J.J., Jenkins M.K., Hamilton S.E., Jameson S.C., et al. CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J. Immunol. 2010; 184(9): 4749–60.Winstead C.J., Reilly C.S., Moon J.J., Jenkins M.K., Hamilton S.E., Jameson S.C., et al. CD4+CD25+Foxp3+ regulatory T cells optimize diversity of the conventional T cell repertoire during reconstitution from lymphopenia. J. Immunol. 2010; 184(9): 4749–60.Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007; 109(8): 3489–95.Avet-Loiseau H., Attal M., Moreau P., Charbonnel C., Garban F., Hulin C., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007; 109(8): 3489–95.

The authors declare that there are no conflicts of interest present.